Peter Rossing

[Peter Rossing @P_Rossing]

see the effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study - https://t.co/AannKA17OJ

[Brendon Neuen @brendonneuen]

"We do much more complicated things, we use much more dangerous drugs for other conditions that don't deliver like this"

"And if you don't do it, you're likely to become obsolete... because someone else will"

Professor Tuttle with a #kidneywk call to arms 🔥🔥🔥 #kidneycompass

[Marie Møller @MarieMoeller_DK]

Dear all,
I will defend my Ph.D. on Friday, November 8th at 2:30 PM at Herlev Hospital, and you are all more than welcome to drop by and listen in.
// Marie

@Stenodiabetes @HerlevGentofte @UCPH_Research @SUHhospital @RikkeBorg @FrederikPersson @DitteHansen7 @IBressendorff

[Peter Rossing @P_Rossing]

No effects of probiotics and fibers on markers of nephropathy, inflammation and intestinal barrier in T1D during a 12w study
https://t.co/kQaMTLQeZ2 @Stenodiabetes @buur_stougaard

[Peter Rossing @P_Rossing]

Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in t2d without CVD https://t.co/VOWkcbRNyt

[Peter Rossing @P_Rossing]

Severely increased albuminuria at screening is a powerful criterion for selecting persons with T1D at high risk of kidney function decline.
https://t.co/7Z8TbzQapJ

[Tor Biering-Sørensen, MD, MSc, MPH, PhD @TorBiering]

Our latest NUDGE trial just published in @JAMA_current 👇

Led by the brilliant @niklasdj1, in collaboration with amazing colleagues from @SSI_dk @harvardmed @Region_Midt and many more.

@CTCPR_ continues to provide important evidence regarding how we can improve public health

[Katalin Susztak @KSusztak]

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial | ⁦@NatureMedicine⁩ Spiro was often discontinued and no effect on outcome https://t.co/uUAa0mfHTj

[@carogomezmartin @carogomezmartin]

Bridging T2D and T1D in CKD treatment

“To generation zero in T1D”

@EASDnews
#Easd2024

@P_Rossing

[Tor Biering-Sørensen, MD, MSc, MPH, PhD @TorBiering]

The first simpub from the @CTCPR_ team during #ESC2024. The NUDGE-FLU-2 trial results in @NatureMedicine lead by @niklasdj1 👇

Electronic nudges for sustained influenza vaccination uptake in older adults (>65): the nationwide randomized NUDGE-FLU-2 trial

https://t.co/qgIQ2G6Q4T

[Brendon Neuen @brendonneuen]

Lovely final slide of the FINEHEART presentation from @mvaduganathan dedicated to the late Professor George Bakris #ESCCongress

[Peter Rossing @P_Rossing]

See the FINE-HEART
all phase 3 studies with finerenone compiled
https://t.co/4RKWl8wBDv

[Peter Rossing @P_Rossing]

See Prof Pratley share Insights from the FLOW Trial | ESC 2024 https://t.co/2cBsadbMJX via @YouTube

[Peter Rossing @P_Rossing]

Bnefit of semaglutide in heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
https://t.co/dKRSKWGfjF

[Peter Rossing @P_Rossing]

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial https://t.co/onHE0GHKmY

[Peter Rossing @P_Rossing]

Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD https://t.co/kowNb62ye4 @Stenodiabetes

[Peter Rossing @P_Rossing]

Effects of Dapagliflozin in Patients with Membranous Nephropathy : looking good, but we will need to learn more
https://t.co/eXEseQ1b2W

[Peter Rossing @P_Rossing]

We are looking for a Statistician for the Epidemiological team in Complications Research @steno diabetes center copenhagen
https://t.co/6jWQbRnI6l

[Peter Rossing @P_Rossing]

Effects of Dapagliflozin in Patients with Membranous Nephropathy looks promising!
https://t.co/ZZne6JtVhB

[Muthu Vaduganathan @mvaduganathan]

*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)!

Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF

Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund

https://t.co/RHM58WTYbq